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Genetic findings of the past years have provided ample evidence for a substantial eti-
ologic heterogeneity of dystonic syndromes. While an increasing number of genes are 
being identified for Mendelian forms of isolated and combined dystonias using classical 
genetic mapping and whole-exome sequencing techniques, their precise role in the 
molecular pathogenesis is still largely unknown. Also, the role of genetic risk factors in 
the etiology of sporadic dystonias is still enigmatic. Only the systematic ascertainment 
and precise clinical characterization of very large cohorts with dystonia, combined with 
systematic genetic studies, will be able to unravel the complex network of factors that 
determine disease risk and phenotypic expression.
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iNTRODUCTiON
Compared to many other neurologic diseases, the dystonias have only relatively recently been recog-
nized as a group of somatic disorders with a characteristic spectrum of clinical manifestations and 
pathophysiological features. Although disturbed signaling of basal ganglia circuits have soon been 
identified as the major neurophysiologic substrate, in the absence of visible pathology on autopsy, 
the cause of what then was called “primary” dystonia, be it focal or generalized, with or without 
additional neurologic abnormalities, remained completely enigmatic. It was only the discovery of the 
torsinA (TOR1A) gene in 1997 (1) as the major cause for primary generalized dystonia, traditionally 
also called “Oppenheim’s dystonia,” that promised to shed more light on the molecular events leading 
to dystonic syndromes, and thus, the ultimate cause of at least a subgroup of dystonic disorders. Yet, 
despite the considerable progress that has been made in the years since this seminal discovery in the 
dissection of the genetic basis of dystonia, in the elucidation of molecular pathways and the develop-
ment of animal models, it must be admitted that the path from mutation to disease is still poorly, 
if at all, understood, and thus, interventions based on a deeper understanding of the molecular 
pathophysiology of the dystonias are still lacking.
In the absence of this understanding, genotype–phenotype correlations were expected to help 
to understand the relationship between the molecular and clinical sphere by describing a more 
or less unequivocal clinical presentation to be associated with, and causally related to a specific 
genetic variant or mutation. While this has been relatively easy for DYT1-dystonia, with TOR1A 
mutations causing a rather specific phenotype of early-onset primary generalized dystonia with 
limb involvement, or in DYT11, the form of myoclonus-dystonia (M-D) caused by mutations in 
the SGCE gene (2), it has become clear that in most other cases, genotype–phenotype correlations 
TABle 1 | list of genes for monogenic forms of isolated and combined dystonias.
locus Disease Type inh. Gene name Chrom.
DYT1 Oppenheim’s torsion dystonia ID AD TorsinA 9q34
DYT2 Early-onset recessive TD ID AR HPCL 1p35
DYT3 Lubag (x-linked dystonia-parkinsonism) CD X-R TAF1 Xq13.1
DYT4 Whispering dystonia (one family only) ID AD TUBB4 –
DYT5a/b Dopa-responsive dystonia CD AD GCH1, TH, SPR 14q22.1
DYT6 Craniocervical dystonia (Mennonite/Amish) ID AD THAP1 8q21-q22
DYT7 Familial torticollis ID AD – 18p
DYT8 Paroxysmal non-kinesigenic choreoathetosis ID/CD AD MR1 2q33-q35
DYT9 Paroxysmal dyskinesias with spasticity CD AD GLUT1 (SLC2A1) 1p21
DYT10 Paroxysmal kinesigenic dyskinesia ID/CD AD PRRT2 16p11.2
DYT11 Myoclonus-dystonia CD AD e-SG 7q21.3
DYT12 Rapid-onset dystonia-Parkinsonism CD AD ATP1A3 19q13
DYT13 Craniocervico brachial ID AD – 1p36
DYT15 Myoclonus-dystonia CD AD – 18p11
DYT16 Dystonia-Parkinsonism CD AR PRKRA 2q31.2
DYT17 Juvenile-onset TD with torticollis and dysarthria CD AR – 20p11
DYT18 Paroxysmal exercise-induced dystonia ID/CD AD GLUT1 (SLC2A1) 1p31
DYT19 Paroxysmal kinesigenic dystonia 2 ID/CD AD – 16q13
DYT20 Paroxysmal non-kinesigenic dystonia 2 ID/CD AD – 2q31
DYT21 Pure dystonia, mixed distribution ID AD – 2q14
DYT23 Cervical dystonia/myoclonus-dystonia ID AD CACNA1B 9q34
DYT24 Mixed dystonia ID AD ANO3 11p14
DYT25 Cervical dystonia ID AD GNAL 18p11
DYT26 Myoclonic dystonia CD AD KCTD17 22q12
DYT27 Cervical/limb/generalized ID AR COL6A3 2q37
Cervical dystonia ID AD CIZ1 9q34
Inh., inheritance mode; Chrom., chromosomal region.
The assignment of a DYT number does not mean that the pathogenic role of mutations in the listed genes is unequivocally confirmed.
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are much more variable and complex than initially believed and 
that genetic classifications do not translate one to one to clinical 
phenotypes. Mutations in some dystonia genes, such as THAP1 
(DYT6), can cause both focal/segmental and generalized forms of 
the disease, while others (e.g., TH or GCH1) may even give rise 
to both isolated and combined dystonias (3). The new classifica-
tion of dystonias proposed by Albanese et al. takes these issues 
into account by clearly separating two “axes” of classification, i.e., 
clinical phenotype and etiology (4).
In addition, the vast majority of patients with the more com-
mon forms of dystonia, such as cervical dystonia, blepharospasm, 
or writer’s cramp, have no or only an uninformative family history 
without clear Mendelian inheritance pattern. Moreover, issues 
including non-penetrance and variable expression of mutations 
even further complicates the distinction between complex and 
heritable forms of dystonia and will be discussed at the end of 
this chapter. Thus, the role of genetic factors in the etiology of 
these forms is still unclear, which has great impact on genetic 
counseling of patients and relatives. Nevertheless, the recognition 
of a small group of patients in whom a dystonia syndrome clearly 
is inherited as a monogenic trait (Table 1) allowed first “genetic 
entry points” and is beginning to give insight into the molecular 
pathogenesis of the disorder.
NOvel GeNeS AND GeNeTiC RiSK 
FACTORS FOR DYSTONiAS
The genetic analysis of the dystonias presents a number of chal-
lenges. At first glance, the presence of a genetic mutation seems 
to be an undisputable and objective finding in a patient with a 
familial neurologic disease. On closer inspection, however, the 
causative role of DNA-sequence variants of a given gene is often 
not easy to elucidate. This is why today the more neutral term 
“genetic variant” is often preferred to the term “mutation,” which 
carries the connotation of being “harmful.” Today it is clear that 
by far not all genetic variants, even in a gene known to be linked to 
a specific inherited disease, are in fact disease causing. Many cases 
with familial dystonia and the vast majority of sporadic cases 
cannot be explained by one or multiple presently recognized and 
validated mutations in known dystonia genes. Two technologies 
are promising to rapidly fill this knowledge gap: (i) whole-exome 
sequencing (WES) and (ii) genome-wide association studies 
(GWAS). While GWAS are designed to detect common (>5% in 
the population) genetic variants that usually reside in non-coding 
(presumably regulatory) regions of the genome and exert only a 
relatively small effect on disease risk, WES targets (usually rare) 
coding variants that are more likely to have a damaging effect on 
protein function.
weS in Dystonia
The part of the human genome that codes for proteins, the coding 
sequence (also called the “exome,” as it is the sum of all exons), 
spans about 50 million base pairs. It contains several million 
rare to very rare variants from the consensus sequence, about 
20,000 in any given individual. More than half of them lead to 
an alteration in the amino acid sequence of the encoded proteins 
(5), and thus can potentially change protein function. A compre-
hensive cataloging of these variants and the elucidation of their 
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functional consequences is a daunting task. Their low frequency 
(usually <1% in the population, often much lower) requires the 
study of very large patient cohorts, and the fact that their effect 
strength is likely to be only moderate (in other words, their 
penetrance on any phenotypic readout is incomplete) means that 
they can be also detected, although at even lower frequencies, in 
asymptomatic individuals. Also, the occurrence and frequency of 
those rare variants varies considerably between populations. This 
means that rare-variant association testing have to be done using 
carefully matched patient/control cohorts. Finally, it is very likely 
that interaction within functional gene networks plays an impor-
tant role in determining overall function, a level of complexity 
that has not yet been addressed in most cases. Sophisticated 
bioinformatics analyses taking into account all these aspects will 
be necessary to make sense of the enormous amounts of data 
generated by WES.
The question of how to validate a potentially pathogenic muta-
tion is of course not restricted to the dystonias or to inherited 
neurologic diseases. Guidelines have been published to establish 
a standardized workflow to assess the causal role of detected vari-
ants (6), but the issue remains challenging and many variants will 
have to be classified as “of unknown significance.” Four lines of 
evidence can support a pathogenic role of a detected variant of 
which each has its merits and its limitations.
 (1) Genetic evidence: co-segregation in a large family with 
demonstration of the variant in multiple affected and 
its absence in unaffected family members remains the 
most stringent proof of pathogenicity. Unfortunately, suf-
ficiently large families are rare, and reduced penetrance 
or non-genetic phenocopies may hamper these analyses. 
Alternatively, a statistically significant enrichment of the 
variant in question in multiple patient cohorts as com-
pared to unaffected controls may serve as genetic evidence 
for pathogenicity. Very large cohorts may be necessary to 
reliably assess the role of rare or very rare variants (with 
population frequencies of ≪0.1%).
 (2) Population evidence: the frequency of an increasing number 
of genetic variants in the population is publicly available in 
a number of databases, such as the exome variant server 
(EVS1) or the ExAC database.2 It is generally assumed that 
variants that are found at a relatively high frequency in such 
databases (e.g., >0.1%) are unlikely to be disease causing 
with high penetrance in rare diseases, because this would 
be incompatible with the epidemiology of these disorders. 
The limitation of these databases however is that they are 
derived from a collection of genetic exome sequencing 
studies, i.e., from patient cohorts with different diseases 
and from different countries. This clinical and demographic 
information is usually not available to users of the database, 
thus introducing unknown biases.
 (3) In silico analysis: freely accessible computer programs have 
been developed to assess the functional consequences of 
1 http://evs.gs.washington.edu/EVS/.
2 http://exac.broadinstitute.org/.
DNA variation, such as PolyPhen3 or SIFT4 or mutation 
taster.5 They are usually based on the analysis of phylo-
genetic conservation (assuming that a change of a highly 
conserved amino acid is more likely to be deleterious than 
more evolutionarily variable ones) or on the predicted 
biophysical consequences of an amino acid exchange. 
While those programs are of value, they are best used to 
provide guidance for further studies, rather than to use 
them to assign a pathogenetic role to a variant in the set-
ting of clinical testing, because their reliability is still in 
question.
 (4) Functional analyses: functional analyses in cellular or 
animal models can provide insight into the consequences 
of a coding mutation of a gene and can even allow to 
identify drug targets and promising lead compounds for 
correcting the dysfunction caused by a mutation. A good 
example is the electrophysiological analysis of mutations 
in ion channel genes using patch clamp techniques in the 
Xenopus oocyte system. However, in the majority of cases, 
the relevant cellular function of a gene product is unknown, 
and thus, it is also unclear if the readout in an artificial 
model system is relevant to the disease under question. The 
generation of transgenic mouse models used to be a time-
consuming and costly procedure; however, the availability 
of the clustered regularly interspaced short palindromic 
repeats (CRISPR)-associated RNA-guided endonuclease 
Cas9 (CRISPR-Cas9) technology opens up new avenues for 
genetic follow-up work as it allows for relatively rapid and 
efficient screening for loss of functional consequences (7). 
Furthermore, in addition to the generation of loss of func-
tion alleles, this technology can be used to introduce human 
mutations directly in the genome of mice creating mouse 
models mimicking human disease and multiple genes can 
be edited at the same time allowing studying gene–gene 
interactions.
So far, WES has already successfully facilitated the discovery 
of several new rare Mendelian dystonia genes (8). For example, 
the genes GNAL and ANO3 have been identified using exome 
sequencing approaches in large families showing clear segregation 
of the mutation with the disease (9, 10). Potentially pathogenic 
variants in these genes have also been found in other, inde-
pendent cohorts (11, 12), which are absent from public exome 
databases, and electrophysiological studies suggested plausible 
functional changes in ion channel and second messenger func-
tion, thus fulfilling all the criteria for pathogenicity, as described 
above. However, the recent findings highlight the challenge 
for future research with the notion that several of the recently 
reported genes, e.g., CIZ1 and COL6A, found in families with 
autosomal dominant and recessive isolated dystonia with cervical 
predominance, respectively (13, 14), could not be unequivocally 
confirmed by other groups (15).
3 http://genetics.bwh.harvard.edu/pph2/.
4 http://sift.jcvi.org/.
5 http://www.mutationtaster.org/.
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GwAS in Dystonia
While exome sequencing aims to identify rare variants thought to 
be disease causing in familial isolated or combined dystonias with 
moderate to high penetrance, GWAS are beginning to explore 
the role of common genetic variability as risk factors for sporadic 
dystonia. Most common variants are located not in the coding 
region of the genome, the exome, but rather in non-coding 
intronic or intergenic regions, or in 3′- or 5′-untranslated regions 
of genes. They do not alter the protein sequence, but rather are 
thought, if they are functional, to modify the expression, the 
regulation, or the use of alternative splice variants of nearby 
(sometimes also far away) genes. Notably, this gene selection may 
be biased for regions that contain multiple genes and have high 
linkage disequilibrium.
GWAS have been extremely successful in identifying dozens of 
risk loci for many neurologic diseases, such as Parkinson’s disease, 
Alzheimer’s disease, or multiple sclerosis (16–18). Usually, very 
large cohorts, in the range of thousands or tens of thousands of 
patients and controls, are needed to reliably detect these risk loci, 
because their individual effects are usually very small, increasing 
the risk to develop the disease under investigation by a factor 
of 1.1–1.5. Thus, this information cannot be used for individual 
genetic counseling, but rather is expected to provide insight 
into the molecular networks underlying the pathogenesis of 
complex disorders. So far, only relatively small GWAS have been 
undertaken in dystonic syndromes. Lohmann et al. decided on 
focusing on a very specific phenotype, musician’s dystonia (MD), 
a form of the disease that affects 1–2% of professional musicians, 
speculating that this restriction would lead to a greater homo-
geneity of the patient sample and thus facilitate the detection of 
risk variants. They found common variants in the arylsulfatase 
G (ARSG) gene in a two-stage design, interrogating cohorts of 
127 MD patients and 984 controls in the exploratory and 116 
patients and 125 healthy musicians in the confirmation cohort 
(19). A single intronic variant was identified in an intron of ARSG 
(rs11655081; P = 3.95 × 10−9); odds ratio, 4.33; 95% confidence 
interval, 2.66–7.05. This variant was also associated with sporadic 
writer’s cramp, a subtype of dystonia thought to be closely related 
to musician’s dystonia (P = 2.78 × 10−2), but not with any other 
focal or segmental dystonia. ARSG hydrolyzes sulfate esters and is 
among others involved in protein degradation (20). The fact that 
dogs carrying homozygous mutations or dogs deficient for ARSG 
develop ceroid lipofuscinosis and accumulate heparin sulfate in 
visceral organs and central nervous system leading to behavioral 
deficits (21, 22) made ARSG an attractive disease gene for musi-
cian’s dystonia. In an attempt to identify the causal mutation in 
ARSG, the coding region of ARSG was screened for mutations 
using Sanger sequencing in Dutch Writer’s Cramp and German 
Musician’s Cramp cohorts (23). Variant rs61999318 (p.Ile493Tyr) 
was significantly enriched in Writer’s Cramp cases compared 
to European Americans in the EVS database (P = 0.0013), but 
no conclusive mutation was identified. Additionally, an overall 
enrichment for rare, protein-changing variants was observed in 
Writer’s Cramp cases compared to controls (P < 0.01), validating 
a role of ARSG in Writer’s Cramp.
In another GWAS, Mok et al. compared 212 cases with cervical 
dystonia with 5,173 controls (24). No single SNP was found to 
be associated on a genome-wide significance level (5 × 10−8), but 
one variant was found to be suggestive near exon 1 of a gene for 
a sodium leak channel (NALCN) with a P-value of 9.76 × 10−7. 
Dysfunction of such an ion channel is a plausible risk factor for 
dystonia, but in another small study, Gómez-Garre et  al. were 
unable to confirm this association (25). The lack of association 
may be due to the fact that not all regions of the genome are 
equally covered, or that despite the large sample size there is lack 
of power to detect low effects, as is often the case for most associ-
ated or the associated gene identified by GWAS. In the end, only 
very large GWA studies including thousands of samples or large 
meta-analysis will be able to unequivocally resolve this issue.
eXAMPle FOR PRiMARY GeNeRAliZeD 
DYSTONiA (DYT1)
Primary generalized dystonia (Oppenheim’s dystonia) is the pro-
totype of a Mendelian form of the disease. It is most frequently, 
and possibly caused by a single specific mutation, a deletion of 
a single GAG triplet encoding a glutamate residue, in exon 5 of 
a gene, TOR1A (1), encoding an ATP-binding protein called 
TorsinA. The protein appears to have chaperone function and is 
located in the nuclear membrane and the endoplasmic reticulum, 
but its precise function is still unknown, and it is completely 
unclear why the loss of a glutamate residue, which is the result 
of the disease-causing GAG deletion mutation, leads to dystonia. 
Even in a relatively “simple” case such as DYT1-dystonia, there 
remain many unanswered questions with respect to genotype– 
phenotype correlations, for example, (i) what determines 
penetrance of the DYT1-mutation, i.e., why do some mutation 
carriers develop the clinically manifest disorder, while many 
others do not and (ii) can mutations other than the classic GAG 
deletion cause dystonia? The answer to both questions could 
provide important insight into the molecular events leading from 
mutation to disease.
Modifiers of the DYT1 Phenotype
Clinically, DYT1-dystonia presents almost always before the 
age of 20  years with an onset in a leg or arm, and progresses, 
not always, but in most cases, to a severe generalized form of 
the disorder (26). Remarkably, only about 30% of carriers of the 
disease-causing GAG deletion develop the disorder, suggesting 
the presence of genetic or non-genetic modifiers. Once the 
critical age is passed, a disease manifestation becomes unlikely, 
in contrast to neurodegenerative disorders. While reduced pen-
etrance is the rule, rather than the exception in all neurogenetic 
disorders including DYT1-dystonia, its determinants are largely 
unknown, but can at least, in part, be explained by genetic 
modifiers. In addition, genetic modifiers may also account for 
differences in phenotypic expression of the GAG deletion leading 
to less common DYT1-dystonia phenotypes including late age 
of onset, focal, or segmental phenotypes and involvement of the 
craniocervical muscles (27).
One of such a genetic modifier variant involved in reduced 
penetrance is a relatively common coding polymorphism in the 
DYT1 gene that affects nucleotide 646 of the cDNA sequence. 
FiGURe 1 | Genomic structure of the TOR1A gene. The penetrance of 
the 946del GAG mutation in exon 5 (E302/303) is modified by polymorphism, 
rs1801968 (p.Asp216His). Reprinted from Ref. (28).
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The respective codon encodes the amino acid aspartate (D) at 
position 216 of the protein (p.216D) (see Figure 1). About 85% 
of all chromosomes in a normal population carry the wild-type 
nucleotide guanosine, while approximately 15% of chromosomes 
carry the variant cytosine at this position, encoding the amino 
acid histidine (H). In itself, this polymorphism has no known 
functional consequence.
However, carriers of the rare histidine variant in trans, i.e., on 
the allele, which does not carry the disease-causing GAG deletion, 
appear to be protected from the deleterious consequences of the 
disease-causing mutation of the TOR1A gene. Risch et al. studied 
a cohort of manifesting and non-manifesting carriers of the GAG 
deletion and found that only about 3% of those with the H-allele 
will eventually show symptoms of dystonia, while penetrance is 
slightly increased, from 30% in all GAG deletion carriers, to 35% 
in those carrying the more common aspartate at position 216 
(28). Obviously, this can explain only a small fraction of the total 
phenotypic variability, because the protective variant is relatively 
rare in the population, but it may serve as an example for other 
diseases and modifiers. A better understanding of this functional 
interaction could also provide interesting hints toward possible 
therapeutic targets.
Do Non-GAG Deletion Mutations in TOR1A 
Cause Dystonia?
The more widespread use of gene sequencing in dystonia patients 
has more recently uncovered a number of additional variants in 
TOR1A in patients with isolated dystonia. This poses the question 
if there is more than one genetic form of DYT1-dystonia. In a 
recent review, Dobričić et al. identified eight non-GAG deletion 
mutations in dystonia patients, most of them occurring in spo-
radic patients with adult onset forms of dystonia (29). This paper 
raises the important problem, how to validate the pathogenicity 
of rare variants detected by targeted or WES.
For TOR1A, for example, more than 100 rare variants are 
documented in the ExAC database, among them the p.Val129Ile 
change that was found in a patient with adult onset cervical 
dystonia by Dobričić et al. (29). While the prediction programs 
assigned the variant the status of “probably disease causing,” and 
it was very rare in the ExAC database (9/121.412 alleles), genetic 
evidence from the family was not supportive (negative family 
history, three unaffected mutation carriers). Population data 
from matched cohorts with and without dystonia or functional 
assays are not available. Thus, the pathogenic role of this variant 
will remain uncertain, and the same is true for other variants in 
TOR1A.
eXAMPleS OF COMBiNeD DYSTONiA 
(PReviOUSlY “DYSTONiA-PlUS” 
SYNDROMeS)
Dystonia may also co-occur with additional movement disorders 
such as Parkinsonism or myoclonus and are then referred to as 
M-D or dystonia with Parkinsonism (e.g., in dopamine-respon-
sive dystonia). In exceptional cases, the dystonia is accompanied 
by other neurological or systemic disorders but these are beyond 
the scope of this article.
Mutations in SGCE Cause  
Myoclonus-Dystonia
Myoclonus-dystonia (M-D) is characterized by the combination 
of focal or segmental dystonia presented as cervical dystonia 
and/or writer’s cramp and shock-like jerks most often affecting 
neck and upper limbs, whereas the legs are less affected. The 
myoclonic jerks can be significantly reduced by the consump-
tion of alcohol. The onset of disease occurs most often in child-
hood but the symptoms can also present in early adulthood. The 
suggested prevalence of MD is about two per million in Europe 
(30). The disease is inherited in an autosomal dominant fashion 
and up to ~30% of the MD cases carry loss of function mutations 
in SGCE encoding epislon sarcoglycan (DYT11) (2), indicating 
that not all SGCE mutations are identified using the current 
technologies and that additional MD genes can be found. 
The identification and functional characterization of these 
novel genes will increase our understanding of the underlying 
molecular biology of MD.
Genetic diagnostics of MD is sometimes complicated by the 
fact that SCGE undergoes maternal genomic imprinting, and 
markedly reduced penetrance is observed in affected families 
in which the mutant allele is silenced when inherited from the 
mother (31). Additionally, extended and complex MD phe-
notypes including cavernous cerebral malformations, hearing 
loss, and dysmorphisms may be the result of the fact that SGCE 
is sometimes deleted together with neighboring genes includ-
ing COL1A2 encoding the collagen alpha-2(1) chain reflecting 
haploinsufficiency of both SGCE and COL1A2 (32). Patients with 
dominant negative mutations in COL1A2 are linked to osteogen-
esis imperfecta types I–IV, Ehlers-Danlos syndrome type VIIB, 
recessive Ehlers-Danlos syndrome classical type, idiopathic 
osteoporosis, and atypical Marfan syndrome (33), whereas hap-
loinsufficiency of COL1A2 leads to milder phenotypes.
Novel Myoclonus-Dystonia Genes
In 2002, a second MD locus was mapped to chromosomal region 
18p11 (DYT15) in a large Canadian family of whom all cases were 
affected by myoclonus and four also displayed limb-dystonia 
(34). Yet, up to date, this finding was not replicated nor was the 
disease gene identified. This further demonstrates the genetic 
heterogeneity of the dystonias. Additionally, given the notion 
that exome sequencing in linkage intervals is quite successful 
6Verbeek and Gasser How Many Dystonias?
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suggests that either the mutation is missed due to (1) low coverage 
of DNA reads as, for example, the mutation may be present in 
a repeat-dense region, (2) the mutation is not covered by the 
exome capturing kit, or (3) the mutation is non-coding.
The successful combination of linkage analysis and exome 
sequencing was recently demonstrated by the identification of 
the disease genes for DYT23 and DYT26 (35, 36). In DYT23, 
a p.Arg1389His variant in CACNA1B encoding the voltage-
gated calcium channel Cav2.2 was reported to cause MD plus in 
a large Dutch family. Cacna1b null mice exhibit a hyperkinetic 
movement disorder (37) and mutations in the homologous 
region of CACNA1A (Cav2.1), the subunit that together with 
Cav2.2 controls depolarization-induced calcium entry and 
transmitter release, were already reported to cause episodic ataxia 
and/or familial hemiplegic migraine (38). These findings support 
a role of Cav2.2 in the etiology of MD. Equally important, the 
p.Arg1389His variant fulfilled the majority of the four lines of 
evidence to support a pathogenic role. The variant (1) segregated 
in the family with the disease, (2) the MAF of the variant is 
<0.1% [carrier frequency of 0.0003809% in the EXAC browser 
(assessed January 2016)], (3) the variant was in silico predicted 
to be damaging, and (4) the variant affected channel functioning 
as was demonstrated by extensive electrophysiological studies 
in cell models. However, no second family carrying mutations 
in CACNA1B was yet identified and screening of an additional 
large European multicenter cohort of MD cases for the presence 
of the p.Arg1389His variant yielded identical frequencies in cases 
versus controls (39). Additionally, given that CACNA1B seems 
like the perfect candidate gene for this dystonia-plus syndrome, 
three other variants segregated with the disease in this family, the 
pathogenicity of the p.Arg1389His variant remains to be further 
confirmed in vivo.
In DYT26, two independent MD families of different 
ethnic background carried a recurrent mutation in KCTD17 
(p.Arg145His) encoding the potassium channel tetrameriza-
tion domain containing 17 (36). This variant was not reported 
in ExAC, but variant p.Arg145Cys was observed with an allele 
frequency of 0.00001656. KCTD17 was shown to operate in a 
large gene cluster involved in calcium-homeostasis and aberrant 
endoplasmatic reticulum calcium signaling was observed in 
fibroblast of patients. Both the genetic findings for DYT23 and 
DYT26 suggested alterations in calcium as pathomechanism 
underlying MD.
eXAMPleS OF DYSTONiA COMBiNeD 
wiTH PARKiNSONiSM
Dopa-Responsive Dystonia
Dopa-responsive dystonia is characterized by a childhood onset 
dystonia with diurnal fluctuations (36). Importantly, the dystonia 
can be ameliorated by l-dopa treatment and Parkinsonism can 
occur later in the disease stage. Dopa-responsive dystonia also 
exhibits reduced penetrance, with unknown origin. Notably, the 
first disease gene that was identified to underlie a Mendelian form 
of dystonia was GTP cyclohydrolase (GCHI) (36). Mutations in 
GCHI led to autosomal dominant inherited dopa-responsive 
dystonia (DYT5a) and GCHI mutation carriers present with 
a childhood dystonia, but adult disease can mimic Parkinson’s 
disease. Up to date, more than 100 different mutations have been 
identified throughout the coding region and 5′UTR region of 
GCHI and no clear genotype–phenotype correlation could be 
established. However, some of the mutations may predispose to 
the risk to develop Parkinson’s disease (40). By sequencing, muta-
tions in GCHI are found in only 40–60% of the dopa-responsive 
dystonias, leaving a large fraction of the patients genetically 
undiagnosed. GTP cyclohydrolase is involved in the production 
of an essential cofactor for biosynthesis of monoamine neu-
rotransmitters, and additionally mutations in other enzymes 
leading to deficiency in the dopamine synthesis were reported to 
cause dopa-responsive dystonia, including tyrosine hydroxylase 
(TH), sepiapterin reductase (SPR), and 6-pyruvoyl tetrahydro-
biopterin (PTP) synthase (41). Patients with mutations in these 
genes present with more severe and complex clinical pictures 
compared to heterozygous GCHI mutation carriers. Notably, 
cases with mutations in genes outside the dopamine synthesis 
pathway such as ATXN3 causing spinocerebellar ataxia type 3 
or SPG11 underlying spastic paraplegia type 11 can manifest 
as a dopa-responsive dystonia (42, 43), thereby broadening the 
clinical and genetic spectrum. With the introduction of exome 
sequencing in the clinic, novel disease genes underlying dopa-
responsive dystonia will be identified.
Rapid-Onset Dystonia-Parkinsonism
Rapid-onset dystonia-Parkinsonism is characterized by a sudden 
onset of dystonia often accompanied with Parkinsonism within 
hours or weeks induced after mental stress or physical trauma. 
The disease is inherited in an autosomal dominant manner 
with reduced penetrance. Heterozygous missense and de novo 
mutations in the Na+/K+-ATPase alpha3 subunit (ATP1A3) 
can cause either rapid-onset dystonia-parkinsonism (DYT12) 
(44), or alternating hemiplegia of childhood (AHC), a severe 
neurodevelopmental syndrome characterized by hemiplegic epi-
sodes and neurological complaints (45), respectively. Notably, no 
DYT12 mutations were reported to cause AHC, whereas in two 
cases the same amino acid was affected. In contrast, some AHC 
cases were reported to develop late-onset rapid-onset dystonia-
Parkinsonism. Both DYT12 and AHC mutations lead to reduced 
ATPase activity, whereas AHC mutations did not affect the protein 
expression level that was observed for DYT12. Recently, a third 
allelic disorder for ATP1A3 was identified, episodic Cerebellar 
Ataxia, Areflexia, Optic Atrophy, and Sensorineural Hearing Loss 
(CAOS) by exome sequencing (45). How different mutations in 
ATP1A3 can lead to three disorders with distinct neurological 
manifestations is not yet known and needs further functional 
investigations but highlights the complexity and challenges of 
current genetics research.
X-linked Dystonia-Parkinsonism (lubag)
X-linked dystonia-Parkinsonism (DYT3) is a recessive condi-
tion characterized by focal dystonia that is later followed by 
Parkinsonism. This rare condition is mainly prevalent in the 
Philippines and affects only males. Several disease-specific 
single-nucleotide changes (DSCs) and a small deletion were 
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detected within TAF1 RNA polymerase II, TATA box-binding 
protein-associated factor, 250  kDa (TAF1) (46). Makino et  al. 
showed that some of these variants are associated with reduced 
neuron-specific TAFI expression (47) that may underlie altered 
expression of genes involved in vesicular transport and dopamine 
metabolism fitting well with the known molecular pathways 
involved in the etiology of dystonia. The question remains if TAF1 
is indeed the DYT3 disease gene and transgenic mouse models 
carrying the various genetic variations in Taf1 are needed to 
answer this question.
DiSCUSSiON AND FUTURe 
PeRSPeCTiveS
While the abovementioned challenges of validating pathogenic 
variants and establishing robust genotype–phenotype correlations 
do not refute the validity of the original findings, it should stress 
the importance of replication of genetic findings. Particularly in 
the setting of genetic counseling of patients and their families, all 
genetic findings have to be treated with caution until unequivocal 
proof of pathogenicity is available. It is likely that over the com-
ing years, dozens, maybe hundreds of genes, will be nominated 
as potential disease or risk genes for dystonia. Their functional 
validation will be a major challenge for neurology, genetics, and 
clinical neuroscience.
Despite these caveats, the identification of more genes causing 
different forms of dystonia will allow to construct an increasingly 
complex network of cellular pathways that promises not only 
to eventually provide a better understanding of the cause(s) of 
dystonia, hopefully leading to new and better treatments, but may 
help us to understand the functions of sensory motor integration 
of the human brain on a molecular level.
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